Medical Cannabis News


This activity may increase antibodies after getting your COVID-19 vaccine

woman working out

A new study shows some interesting evidence in regards to antibodies and what’s safe to do right after getting a vaccine.

Vaccines prompt an immune reaction from your body, creating antibodies and protecting you from a virus. It’s understood that the stronger your reaction, the better and more thorough your protection will be, with your body producing the necessary antibodies to fight off the virus when exposed to it in the future. A new study found that exercising after getting your COVID-19 shot might help you produce even more antibodies. Published in the Journal of Brain, Behavior and Immunity, the study found that active adults who worked out for over 90 minutes after getting their vaccine demonstrated increased serum antibodies.


Could Medical Cannabis Tackle Obesity?

person grabbing belly

Western Australia’s Little Green Pharma (ASX:LGP) and Curtin University have teamed up to investigate the potential of medicinal cannabis treatment options for obesity and related health issues.

Marijuana is well-known for causing the “munchies“, which is thought to be caused by the cannabinoid tetrahydrocannabinol (THC) – the same compound that creates marijuana’s high. But cannabis is much more than THC as you’ll see on HG’s big list of cannabinoids.

New research at Curtin’s Medical School will attempt to identify combinations of cannabinoids that may produce effects of a feeling of fullness; decreasing appetite.


Cannabis shown to be an effective treatment option for back pain: Study review

female holding back in pain

A systematic review by a team of researchers affiliated with the Swedish Neuroscience Institute in Seattle, Wash., have found cannabis to be an effective treatment for back pain.

Published in Global Spine Journal, the researchers reviewed four studies composed of 110 patients.

“In each study, there was a quantifiable advantage of cannabis therapy for alleviating back pain. There were no serious adverse effects reported,” researchers wrote.


Of the four studies that met the criteria for review, one was conducted in Austria while the remaining three were based in the U.S. The majority of study participants were women (86 per cent) with an average age of 45.


Tilray Launches Medical Cannabis Products in Malta

Tilray Medical logo

LEAMINGTON, Ontario, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has completed its first sale of medical cannabis in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.


Plan for Isle of Man medicinal cannabis facility

rendering of Isle of Man cannabis facitily

A science and innovation centre and sustainable energy park are also part of Peel NRE’s plans for 72 acres of land off Cooil Road in Braddan.

Peel has launched a consultation for the project, which it says could bring between £90m and £180m of investment to the island’s economy. It would also create local jobs in a variety of fields, including botany, research, technology and security.

In January 2021, the Isle of Man passed a resolution to legalise the growing, production and export of medicinal cannabis. It is still not, however, legal to consume medicinal cannabis on the island.


Creso Pharma developing hemp based CBDA lozenge

cannabis plants

Australia’s Creso Pharma Limited (ASX:CPH) says it has reached final stage of development for a new hemp-based lozenge product containing cannabidiolic acid (CBDA).

The cannabinoids CBD (cannabidiol) and THC (tetrahydrocannabinol) tend to steal the limelight, but there are many other cannabinoids in cannabis; among them CBDA.

CBDA hit the headlines recently when University of Oregon researchers suggested it could prevent the coronavirus ( SARS-CoV-2) causing COVID-19 from invading human cells. The important thing to note is further CBDA research is needed and a conclusion as to its efficacy may be some way off, although CBDA clinical trials may start soon. Creso Pharma notes it has not carried out any of its own research in relation to CBDA and SARS-CoV-2.


Hemp Oil Can Lower Your Cholesterol According to a New Medical Study

hemp oil

According to the Centers for Disease Control, a little over more than half of the American adult population are medicating with cholesterol-lowering drugs.

And while high cholesterol is a problem usually associated with the obese or elderly, the truth is that a worrisome population of adults aged 20 and up already have elevated cholesterol levels. It’s far too easy to get high cholesterol given the standard American diet, which is loaded in sugars, saturated fats, and trans fats.


How Psychiatry Shaped My View of Cannabis

Practicing psychiatry offers perspective on cannabis's popularity and risks.

The privilege granted psychiatrists to hear the most intimate facets of people’s lives, combined with the authority and responsibility to administer medications appropriately and safely, gives them a unique perspective on cannabis use.


Canada’s Reforms on Psychedelics Are Slowly Taking Shape


Financial rewards will wait, but there’s optimism

Scott Atkinson, a 49-year-old Canadian who fought in Afghanistan and suffers from PTSD, recently became one of the first people to apply for MDMA treatment in Canada following a legal change that companies believe will make it easier to get psychedelic treatments.

His Jan. 6 application came through a revised program that considers doctor-approved recommendations for treatment with psychedelic drugs. It helps explain why Canada is seeing renewed optimism around psychedelic drugs — even if the financial rewards may be a long way off.


Health Canada denies health care practitioners access to psilocybin for training purposes


The federal agency previously granted Section 56 exemptions to 19 health care professionals in December 2020, allowing them to take part in a historic training program.

About a month after Health Canada amended the Special Access Program (SAP), allowing physicians to request patient access to restricted drugs, the federal agency has denied dozens of health care professionals Section 56 exemptions to psilocybin for training purposes.

The surprising move was announced on Twitter by B.C.-based TheraPsil, a non-profit dedicated to providing access to psilocybin therapy. 


Subscribe to RSS - Medical Cannabis News